Spartalis Eleftherios, Athanasiadis Dimitrios I, Chrysikos Dimosthenis, Spartalis Michael, Boutzios Georgios, Schizas Dimitrios, Garmpis Nikolaos, Damaskos Christos, Paschou Stavroula A, Ioannidis Argyrios, Tsourouflis Gerasimos, Dimitroulis Dimitrios, Nikiteas Nikolaos I
Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, Medical School, National and Kapodistrian University of Athens, Athens, Greece
1st Department of Surgery, "Papageorgiou" General Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Anticancer Res. 2019 Mar;39(3):1119-1127. doi: 10.21873/anticanres.13220.
BACKGROUND/AIM: Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies, remaining generally incurable. Histone deacetylase (HDAC) seems to play a role in regulating transcription of genes involved in ATC, making HDAC inhibitors (HDACI) promising anticancer drugs for ATC. The purpose of this review was to evaluate the role of HDACIs in ATC treatment and describe the latest trends of current research on this field. MATERIALS AND METHODS: This literature review was performed using the MEDLINE database. The keywords/phrases were; thyroid cancer, anaplastic, HDAC, histone, deacetylase*, HDACI. RESULTS: Compounds, such as SuberoylAnilide Hydroxamic Acid, valproic acid, sodium butyrate, butyrate, phenylbutyrate, trichostatin A, AB1-13, panobinostat or LBH589, belinostat, MS-275, depsipeptide, CUDC101, CUDC907, N-Hydroxy-7-(2-naphthylthio)-Hepanomide (HNHA), and PXD101 have shown promising antitumor effects against ATC. CONCLUSION: HDACIs represent a promising therapy for ATC management, both as monotherapy and in combination with other anticancer drugs.
背景/目的：间变性甲状腺癌（ATC）是最具侵袭性的人类恶性肿瘤之一，通常仍无法治愈。组蛋白去乙酰化酶（HDAC）似乎在调控与ATC相关的基因转录中发挥作用，这使得HDAC抑制剂（HDACI）成为治疗ATC的有前景的抗癌药物。本综述的目的是评估HDACI在ATC治疗中的作用，并描述该领域当前研究的最新趋势。 材料与方法：本综述使用MEDLINE数据库进行。关键词/短语为：甲状腺癌、间变性、HDAC、组蛋白、去乙酰化酶*、HDACI。 结果：诸如辛二酰苯胺异羟肟酸、丙戊酸、丁酸钠、丁酸、苯丁酸钠、曲古抑菌素A、AB1-13、帕比司他或LBH589、贝利司他、MS-275、缩肽、CUDC101、CUDC907、N-羟基-7-（2-萘硫基）庚酰胺（HNHA）和PXD101等化合物已显示出对ATC有前景的抗肿瘤作用。 结论：HDACI无论是作为单一疗法还是与其他抗癌药物联合使用，都是治疗ATC的有前景的疗法。
Anticancer Res. 2019-3
Curr Pharm Des. 2021
Anticancer Res. 2016-10
Technol Cancer Res Treat. 2023
Pharmaceuticals (Basel). 2023-4-7
Cancer Diagn Progn. 2023-3-3
Zotero 插件